Balaxi Pharma Share Price Rises 10% After Q4 FY25 Results Despite Weaker Earnings

Market Performance

Balaxi Pharma's share price surged by 10% on June 2, registering a strong upward move despite reporting a weaker financial performance for Q4 FY25. The small-cap stock, which trades below ₹100, touched an intraday high of ₹57.24, marking a 14.5% spike during trading hours on the NSE.

However, despite this sharp rally, the stock has struggled over the longer term:

• Down 58% in the last 1 year
• Fell 9% in May 2025
• Dropped nearly 14% in April
• Had a brief rebound of 20% in March
• Underperformed for seven consecutive months (Aug 2024 – Feb 2025)

Q4 FY25 Financial Snapshot

Balaxi Pharmaceuticals reported a weaker set of earnings for the quarter ended March 2025, with declines across key financial metrics. Here's a breakdown of the performance:

Revenue

• ₹996.98 lakh in Q4 FY25
• Down 37.9% YoY from ₹1,606.86 lakh in Q4 FY24
• Down 29% QoQ from ₹1,407.49 lakh in Q3 FY25

Net Profit / Loss

• Net loss of ₹117.85 lakh in Q4 FY25
• Wider than the ₹57.52 lakh loss in Q4 FY24
• Shift from ₹174.32 lakh net profit in Q3 FY25 to a loss

The decline is attributed to margin pressure, weak revenue performance, and increased input and operational costs.

Full-Year FY25 Performance

While Q4 was weak, the company maintained overall profitability for the year ended March 31, 2025:

• Net profit: ₹360.13 lakh (vs ₹365.04 lakh in FY24)
• Revenue from operations: ₹6,098.82 lakh
• 5.6% decline from ₹7,019.60 lakh in FY24

Key Shareholding Developments

Earlier this year, a significant bulk deal on March 3, 2025, stirred investor interest:

• Ebisu Global Opportunities Fund Ltd acquired 45.21 lakh shares (8.19%) @ ₹53
• Unico Global Opportunities Fund Ltd picked up 45.77 lakh shares (8.3%) @ ₹53
• Sellers: MGC Fund Ltd and Elala India Opportunities Fund

These movements indicate a reshuffling of large investors, which likely influenced recent market activity in the Balaxi Pharma share price.

Company Profile

Balaxi Pharmaceuticals is a healthcare player focused on branded formulations with intellectual property rights. The company:

• Targets emerging markets
• Operates in Latin America, Africa, and the Caribbean
• Offers a diverse product range across multiple therapeutic segments
• Leverages an expansive distribution network

Summary

Despite a disappointing Q4 performance, Balaxi Pharma's share price rallied sharply on June 2, buoyed by bulk deal activity and investor sentiment. While the company managed to stay profitable for the whole year, it faces ongoing challenges with revenue and margins. As a small-cap stock trading under ₹100, it remains on the radar for volatility and potential value-driven interest.